Ranolazine attenuates behavioral signs of neuropathic pain

Harry J. Gould; Colleen Garrett; Renee R. Donahue; Dennis Paul; Ivan Diamond; Bradley K. Taylor

doi:10.1097/FBP.0b013e3283323c90

Ranolazine attenuates behavioral signs of neuropathic pain

Harry J. Gould, Colleen Garrett, Renee R. Donahue, Dennis Paul, Ivan Diamond, Bradley K. Taylor

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.

Original language	English (US)
Pages (from-to)	755-758
Number of pages	4
Journal	Behavioural Pharmacology
Volume	20
Issue number	8
DOIs	https://doi.org/10.1097/FBP.0b013e3283323c90
State	Published - Dec 2009
Externally published	Yes

Keywords

Allodynia
Hyperalgesia
Na 1.7
NaV 1.8
Rat
Spared nerve injury

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1097/FBP.0b013e3283323c90

OpenUrl availability

Full text

Cite this

@article{736a3b932947404399ca26c9933caf5f,

title = "Ranolazine attenuates behavioral signs of neuropathic pain",

abstract = "Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.",

keywords = "Allodynia, Hyperalgesia, Na 1.7, NaV 1.8, Rat, Spared nerve injury",

author = "Gould, {Harry J.} and Colleen Garrett and Donahue, {Renee R.} and Dennis Paul and Ivan Diamond and Taylor, {Bradley K.}",

year = "2009",

month = dec,

doi = "10.1097/FBP.0b013e3283323c90",

language = "English (US)",

volume = "20",

pages = "755--758",

journal = "Behavioural Pharmacology",

issn = "0955-8810",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - Ranolazine attenuates behavioral signs of neuropathic pain

AU - Gould, Harry J.

AU - Garrett, Colleen

AU - Donahue, Renee R.

AU - Paul, Dennis

AU - Diamond, Ivan

AU - Taylor, Bradley K.

PY - 2009/12

Y1 - 2009/12

N2 - Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.

AB - Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.

KW - Allodynia

KW - Hyperalgesia

KW - Na 1.7

KW - NaV 1.8

KW - Rat

KW - Spared nerve injury

UR - http://www.scopus.com/inward/record.url?scp=73949141073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949141073&partnerID=8YFLogxK

U2 - 10.1097/FBP.0b013e3283323c90

DO - 10.1097/FBP.0b013e3283323c90

M3 - Article

C2 - 19773645

AN - SCOPUS:73949141073

SN - 0955-8810

VL - 20

SP - 755

EP - 758

JO - Behavioural Pharmacology

JF - Behavioural Pharmacology

IS - 8

ER -

Ranolazine attenuates behavioral signs of neuropathic pain

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this